The joint office for Southern Africa for DNDi and the Global Antibiotic R&D Partnership (GARDP) was opened in November 2017.
DNDi projects
Joint office Southern Africa – for DNDi & GARDP
Brickfield Canvas, Unit 12, 1st Floor
35 Brickfield Road
Woodstock
Cape Town 7195
South Africa
dndi-gardp-southafrica@dndi.org
Highlights
2019
- R&D: Prepared GARDP Phase III study for gonorrhoea and Phase II for neonatal and paediatric sepsis, both due to start enrolment in 2020
- Partnerships: Supported stakeholder efforts to advance treatment access for cryptococcal meningitis with DNDi, and coordinated with research partners for GARDP studies
2018
- Continued to strengthen its collaborative efforts with the South African Medical Research Council (SAMRC). SAMRC provided 4 million Rand (~240,000 EUR) to further GARDP’s activities in South Africa to deliver affordable, new or improved antibiotic treatments for drug-resistant bacterial infections, beginning with neonatal sepsis and sexually-transmitted infections.
- Supported GARDP‘s launch of a global observational study of babies with sepsis, with three South African sites, to guide development of new and improved antibiotic treatments for newborns.
- Recruited a locally based team to provide support to the launch and execution of clinical trials in South Africa
2017
- Opening of a new DNDi-GARDP joint office in Cape Town
- Collaboration agreement with South African Medical Research Council
